Federal Cannabis Policy — Marijuana's Legal Limbo Between State & Federal Law
Marijuana (cannabis) remains a Schedule I controlled substance under federal law — classified alongside heroin and LSD as having "no currently accepted medical use" and a "high potential for abuse" (21 U.S.C. § 812). Federal penalties for manufacturing, distributing, or possessing marijuana include imprisonment and fines (21 U.S.C. § 841). Yet as of 2026, 24 states plus D.C. have legalized recreational marijuana, 38 states have legalized medical marijuana, and the legal cannabis industry generates approximately $30 billion in annual revenue. This creates the most significant federal-state conflict in American law since Prohibition: activities that are legal under state law remain federal crimes. The federal government has addressed this conflict primarily through enforcement discretion — choosing not to prosecute most state-legal cannabis activity — rather than changing the law. The Cole Memo (2013, rescinded 2018) articulated DOJ's approach of deferring to state regulatory systems. Congressional appropriations riders (the Rohrabacher-Blumenauer amendment, annually renewed since 2014) prohibit the DOJ from using funds to interfere with state medical marijuana programs. The SAFE Banking Act — which would allow banks to serve state-legal cannabis businesses without fear of federal money laundering charges — has passed the House multiple times but has not been enacted. In 2022, the Biden administration initiated a process to reschedule marijuana from Schedule I to Schedule III — which would acknowledge its medical use, reduce federal criminal penalties, and potentially open the door to federal tax deductions for cannabis businesses — but rescheduling does not legalize recreational use.
Current Law (2026)
| Parameter | Value |
|---|---|
| Federal classification | Schedule I (21 U.S.C. § 812) — "no currently accepted medical use," high abuse potential |
| Federal penalties | Manufacturing/distribution: up to life imprisonment (quantity-dependent); simple possession: up to 1 year (first offense) |
| State legalization | 24 states + D.C. (recreational); 38 states (medical) |
| Industry size | ~$30 billion annual revenue (state-legal market) |
| Rescheduling | Process initiated 2022 — proposed move to Schedule III (medical use acknowledged, lower penalties) |
| Appropriations rider | Rohrabacher-Blumenauer amendment — prohibits DOJ from interfering with state medical marijuana laws |
| Banking | Federal banking access severely restricted — cannabis businesses operate largely in cash |
| Tax | 26 U.S.C. § 280E — cannabis businesses cannot deduct ordinary business expenses (applies to Schedule I/II substances) |
Legal Authority
- 21 U.S.C. § 811 — Scheduling authority (Attorney General may add, remove, or reschedule substances; DEA initiates scheduling proceedings; HHS provides binding scientific and medical findings)
- 21 U.S.C. § 812 — Schedules of controlled substances (marijuana is Schedule I — the most restrictive category: high abuse potential, no currently accepted medical use in the U.S., lack of accepted safety for use under medical supervision)
- 21 U.S.C. § 841 — Prohibited acts (unlawful to manufacture, distribute, dispense, or possess with intent to distribute; quantity-based mandatory minimums apply)
- 21 U.S.C. § 844 — Simple possession penalties (first-offense possession of any controlled substance: up to 1 year and $1,000 minimum fine; additional offenses carry escalating penalties)
- 21 U.S.C. § 846 — Attempt and conspiracy (attempting or conspiring to commit any CSA trafficking offense carries the same penalties as the completed offense — critical for prosecuting drug distribution networks)
- 21 U.S.C. § 862a — Denial of federal benefits (individuals convicted of drug-related offenses may be denied certain federal benefits; states can opt out)
- 26 U.S.C. § 280E — Denial of deductions for expenditures in connection with trafficking in controlled substances
- Rohrabacher-Blumenauer Amendment — Annual appropriations rider prohibiting DOJ from using funds to prevent states from implementing their medical marijuana laws
How It Works
Federal law prohibits all marijuana activities — growing, selling, possessing, even using — while state law in 24+ states allows recreational use by adults 21+ with licensed cultivation, manufacturing, testing, and retail sale. Under the Supremacy Clause, federal law is supreme, meaning federal agents could theoretically arrest someone operating a state-licensed dispensary, but the federal government has largely chosen enforcement restraint for state-legal activities, focusing resources on large-scale trafficking, cartel operations, and sales to minors. That restraint is prosecutorial policy, not statute; a new Attorney General could change priorities without any change in law. The most tangible federal impact on state-legal cannabis businesses comes from 26 U.S.C. § 280E: businesses trafficking in Schedule I or II controlled substances may not deduct ordinary business expenses — rent, payroll, utilities — from their federal taxes, only cost of goods sold, resulting in effective federal tax rates of 40–70% far exceeding any other legal industry. Rescheduling marijuana to Schedule III would eliminate § 280E because the provision applies only to Schedule I and II substances. Banks and credit unions that serve cannabis businesses face potential money laundering liability and aiding-and-abetting charges under the Bank Secrecy Act, forcing a $30 billion industry to operate largely in cash — creating safety risks, tax collection difficulties, and regulatory opacity. The SAFE Banking Act, which would create a safe harbor for financial institutions serving state-legal cannabis businesses, has passed the House seven times but has not cleared the Senate.
The Biden administration's rescheduling proposal would move marijuana from Schedule I to Schedule III — acknowledging accepted medical use and lower abuse potential — which would eliminate § 280E, allow federally funded research, and reduce federal criminal penalties, but would not legalize recreational marijuana. Cannabis would still be a controlled substance requiring DEA registration, and state recreational programs would technically continue to conflict with federal law. Descheduling (removing marijuana from the controlled substances schedule entirely) would go further, leaving regulation to states; full legalization would require Congress to enact a federal regulatory framework. Congress has addressed the conflict through annual appropriations riders since 2014: the Rohrabacher-Blumenauer amendment prohibits DOJ from using appropriated funds to prevent states from implementing their own medical marijuana laws, and federal courts have interpreted this to block prosecutions of individuals complying with state medical programs — though the amendment must be renewed each fiscal year and has not been extended to cover recreational programs.
How It Affects You
If you use cannabis in a state where it's legal and are wondering about federal consequences: Your state-legal activity remains a federal crime under the Controlled Substances Act — simple possession is a misdemeanor (up to 1 year); distribution is a felony. The practical risk of federal prosecution for personal use is very low, and has been deliberately deprioritized by DOJ. But federal consequences extend well beyond prosecution. Federal housing: Public housing and HUD-assisted housing programs prohibit admission or tenancy for anyone convicted of a drug-related offense, and landlords can prohibit marijuana use even in legal states. Federal employment: All federal employees and contractors subject to the Drug-Free Workplace Act can be tested for marijuana; a positive test is grounds for termination regardless of state law. Security clearances: The intelligence community and DOD adjudicate security clearances using federal law — recent marijuana use can disqualify a clearance applicant, though the criteria have loosened somewhat in recent years for light historical use. Immigration: Any marijuana use — including in legal states — can be treated as inadmissibility or deportability for non-citizens, even lawful permanent residents. Green card holders and visa holders should treat federal cannabis law, not their state's law, as controlling.
If you own or are considering starting a cannabis business in a legal state: The biggest federal problem you face daily isn't prosecution — it's taxes. 26 U.S.C. § 280E prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses from federal taxable income. You can only deduct cost of goods sold. The result: effective federal tax rates of 40-70% for cannabis businesses, compared to 21% for most corporations. A dispensary with $5 million in revenue and $2 million in gross profit might pay $800,000-$1,400,000 in federal taxes rather than the $420,000 a comparable non-cannabis business would owe. The Biden administration's rescheduling proposal (Schedule I → Schedule III) would eliminate the 280E problem, since the provision only applies to Schedule I and II substances — but as of 2026, the rescheduling process is pending and 280E applies. Structure carefully: COGS maximization (the only deductions available) and entity structure (C-corp vs. pass-through) are critical tax planning elements that require a CPA with cannabis-specific expertise.
If you're a federal employee, security clearance holder, or military member: Cannabis use is incompatible with federal employment standards regardless of state law. Federal workplace drug testing doesn't recognize state legalization — a positive marijuana test is treated the same in Colorado as in Alabama for federal employees. If you hold a security clearance, recent use will be evaluated against guidelines that have been updated to recognize that youthful or infrequent past use is not automatically disqualifying — but current regular use is treated as a sign of poor judgment and potential foreign intelligence vulnerability. Military members are subject to the UCMJ, which doesn't recognize state marijuana laws; use can result in discharge. Contractors subject to agency drug testing policies are in the same position as federal employees. If you're applying for a federal job or clearance and have used cannabis, honesty and demonstrating that past use is in the past is generally the right approach; lying is always worse than the underlying conduct.
If you work in banking, financial services, or are a cannabis business seeking banking services: Federal banking law is the second major structural problem for the cannabis industry after 280E. Banks and credit unions that provide accounts, loans, or other services to marijuana businesses face potential federal criminal liability for money laundering and aiding and abetting drug trafficking under the Bank Secrecy Act — even in states where the activity is legal. FinCEN issued guidance in 2014 establishing a "marijuana limited" filing category for banks willing to serve cannabis businesses with extensive due diligence, but most major banks decline the risk. The result is a $30 billion industry operating largely in cash — creating $50-100+ million in annual losses to robbery and theft, and making state tax collection and regulatory compliance harder. The SAFE Banking Act (which would create explicit safe harbors for financial institutions serving state-legal cannabis businesses) has passed the House seven times but not the Senate. Until federal legislation passes, cannabis businesses must use one of the ~700 financial institutions that have established cannabis banking programs — often smaller credit unions and community banks — typically with higher fees, limited services, and significant compliance burdens.
State Variations
Cannabis legalization varies enormously by state:
- Recreational legal (24 states + D.C.): Licensed retail sales to adults 21+; tax rates range from 10% to 37%
- Medical only (14 additional states): Requires physician recommendation; qualifying conditions vary
- Fully illegal: A shrinking number of states maintain full prohibition
- Tax structures: States tax cannabis by weight, price, THC content, or a combination — rates and structures vary dramatically
- Social equity: Many states include programs for communities disproportionately affected by marijuana criminalization
Implementing Regulations
- 21 CFR Part 1308 — DEA Schedule I controlled substance listings; marijuana/cannabis remains classified as Schedule I, determining federal enforcement authority, research restrictions, and criminal penalties
- 21 CFR Part 1301 — DEA registration requirements for cannabis researchers; researchers must obtain Schedule I researcher registration to conduct federally authorized cannabis studies
- 7 CFR Part 990 — USDA Domestic Hemp Production Program (hemp defined as cannabis with ≤0.3% THC delta-9, legalized under the 2018 Farm Bill and subject to USDA regulatory oversight)
- 31 CFR Part 1010 — FinCEN Bank Secrecy Act guidance on cannabis-related financial services; establishes due diligence requirements for financial institutions willing to serve state-licensed cannabis businesses
Pending Legislation
Cannabis rescheduling, banking access (SAFE Banking Act), and decriminalization bills have been introduced in the 119th Congress. See Controlled Substances Act and state marijuana-federal conflict for related legislative activity.
Recent Developments
The DEA's rescheduling process (initiated at HHS recommendation in 2022) is the most significant federal cannabis policy development in decades — a proposed rule to move marijuana to Schedule III was published for public comment. If finalized, it would eliminate the § 280E tax penalty, facilitate research, and signal federal acknowledgment of marijuana's medical value — but would not legalize recreational use. The SAFE Banking Act continues to pass the House but stall in the Senate. Cannabis remains the most prominent example of the federal-state policy conflict — with the practical reality of a legal $30 billion industry operating in tension with its classification as a Schedule I narcotic. The 2024 elections brought additional states into the recreational legalization column, continuing the trend toward nationwide state-level legalization operating alongside federal prohibition.
- DEA Schedule III rescheduling stalled (2025): The DEA's proposed rule to reschedule marijuana from Schedule I to Schedule III — which would have eliminated the § 280E tax treatment and opened research — was effectively frozen under the Trump administration. The ALJ hearing process creates structural delay. Without rescheduling, cannabis businesses continue paying effective federal tax rates of 60-70% (unable to deduct ordinary business expenses under § 280E) while competing in legal state markets.
- SAFE Banking Act stalled again (2025): Despite passing the House five times since 2019, the SAFE Banking Act — allowing banks to serve cannabis businesses without federal prosecution risk — has not cleared the Senate. An estimated 72% of cannabis retailers remain unbanked or underbanked, operating cash-only with public safety and tax compliance risks.
- State legalization at 24 states (2026): As of 2026, 24 states and D.C. have legalized recreational cannabis; 38 states permit medical cannabis. Florida voters narrowly rejected legalization in 2024 (56% for, short of 60% supermajority). Ohio approved recreational cannabis in 2023. The $30+ billion legal state market continues to expand while federal prohibition persists.
- Trump DOJ enforcement posture: The Trump DOJ has signaled it will not prioritize enforcement against state-legal cannabis businesses complying with state law, consistent with the Cole Memo framework (rescinded by Sessions in 2018 but largely followed in practice). However, the lack of a formal non-enforcement policy leaves businesses, banks, and landlords operating with legal uncertainty that only legislation or rescheduling can resolve.